Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internship and Residency | 12 | 2025 | 805 | 3.240 |
Why?
|
| Pancreatic Neoplasms | 13 | 2017 | 354 | 2.350 |
Why?
|
| General Surgery | 5 | 2025 | 211 | 1.680 |
Why?
|
| Carcinoma, Pancreatic Ductal | 9 | 2015 | 128 | 1.590 |
Why?
|
| Pancreatectomy | 6 | 2016 | 99 | 1.270 |
Why?
|
| Pancreatitis | 3 | 2020 | 97 | 1.150 |
Why?
|
| Education, Medical, Graduate | 6 | 2025 | 348 | 1.080 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 1222 | 1.040 |
Why?
|
| Endrin | 1 | 2024 | 4 | 0.830 |
Why?
|
| Mastectomy | 3 | 2024 | 56 | 0.820 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2015 | 31 | 0.770 |
Why?
|
| Nerve Block | 1 | 2024 | 61 | 0.760 |
Why?
|
| Carcinoma, Papillary | 4 | 2015 | 37 | 0.690 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 27 | 0.580 |
Why?
|
| Social Media | 1 | 2021 | 128 | 0.570 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 150 | 0.560 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2016 | 62 | 0.560 |
Why?
|
| Databases, Factual | 2 | 2019 | 882 | 0.540 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 112 | 0.540 |
Why?
|
| Students, Medical | 1 | 2020 | 263 | 0.520 |
Why?
|
| Humans | 39 | 2025 | 65121 | 0.510 |
Why?
|
| Retrospective Studies | 15 | 2024 | 6862 | 0.490 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.480 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.480 |
Why?
|
| Hemangioma | 1 | 2016 | 27 | 0.470 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 21 | 0.460 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 114 | 0.430 |
Why?
|
| Genetic Testing | 1 | 2015 | 141 | 0.420 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 286 | 0.420 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 173 | 0.410 |
Why?
|
| Clinical Competence | 4 | 2024 | 727 | 0.400 |
Why?
|
| Pancreas | 2 | 2013 | 154 | 0.390 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1322 | 0.390 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 309 | 0.380 |
Why?
|
| Female | 23 | 2025 | 34013 | 0.380 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 5 | 0.380 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 26 | 0.370 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 4 | 0.370 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 30 | 0.360 |
Why?
|
| Lymph Nodes | 1 | 2013 | 232 | 0.360 |
Why?
|
| Burnout, Professional | 2 | 2023 | 142 | 0.320 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 2483 | 0.310 |
Why?
|
| Stomach | 1 | 2010 | 87 | 0.310 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2763 | 0.310 |
Why?
|
| Suture Techniques | 1 | 2010 | 94 | 0.300 |
Why?
|
| Hospital Units | 1 | 2008 | 9 | 0.280 |
Why?
|
| Gallstones | 1 | 2008 | 25 | 0.280 |
Why?
|
| Middle Aged | 14 | 2019 | 18264 | 0.280 |
Why?
|
| Male | 19 | 2025 | 31039 | 0.270 |
Why?
|
| Hospital Costs | 1 | 2008 | 126 | 0.260 |
Why?
|
| Personnel Selection | 2 | 2025 | 57 | 0.260 |
Why?
|
| Patient Admission | 1 | 2008 | 198 | 0.240 |
Why?
|
| Risk Factors | 5 | 2019 | 5429 | 0.240 |
Why?
|
| Prognosis | 5 | 2019 | 1785 | 0.230 |
Why?
|
| Internal Medicine | 2 | 2023 | 155 | 0.230 |
Why?
|
| United States | 7 | 2025 | 8094 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2022 | 2619 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 415 | 0.220 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 90 | 0.220 |
Why?
|
| Aged | 12 | 2017 | 14955 | 0.220 |
Why?
|
| Specialty Boards | 1 | 2024 | 15 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 59 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 91 | 0.210 |
Why?
|
| Feedback | 1 | 2023 | 91 | 0.190 |
Why?
|
| Educational Measurement | 1 | 2024 | 213 | 0.190 |
Why?
|
| Pandemics | 3 | 2023 | 675 | 0.190 |
Why?
|
| Preoperative Care | 3 | 2019 | 199 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 5609 | 0.180 |
Why?
|
| Motivation | 1 | 2023 | 296 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 373 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 930 | 0.160 |
Why?
|
| Canada | 1 | 2020 | 154 | 0.160 |
Why?
|
| Survival Rate | 2 | 2012 | 844 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2023 | 1015 | 0.160 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 213 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2703 | 0.160 |
Why?
|
| Veins | 1 | 2020 | 63 | 0.160 |
Why?
|
| Inservice Training | 1 | 2020 | 85 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2020 | 2102 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2023 | 169 | 0.150 |
Why?
|
| Research Design | 1 | 2023 | 588 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2019 | 6 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2017 | 5785 | 0.150 |
Why?
|
| Adult | 9 | 2023 | 17356 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 58 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 92 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 526 | 0.140 |
Why?
|
| Learning | 1 | 2020 | 186 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 40 | 0.140 |
Why?
|
| Young Adult | 3 | 2016 | 4810 | 0.140 |
Why?
|
| Hepatectomy | 1 | 2019 | 63 | 0.140 |
Why?
|
| Incidence | 2 | 2019 | 1418 | 0.140 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 16 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 12 | 0.140 |
Why?
|
| Mutation | 4 | 2015 | 2658 | 0.130 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 12 | 0.120 |
Why?
|
| Methylene Blue | 1 | 2016 | 23 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 39 | 0.120 |
Why?
|
| Coloring Agents | 1 | 2016 | 50 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 608 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 704 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 525 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 50 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 12 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 287 | 0.110 |
Why?
|
| Diet | 1 | 2019 | 536 | 0.110 |
Why?
|
| ras Proteins | 1 | 2015 | 76 | 0.110 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 22 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 544 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 3762 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 464 | 0.100 |
Why?
|
| Nomograms | 1 | 2013 | 20 | 0.100 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 225 | 0.100 |
Why?
|
| Hepatic Artery | 1 | 2013 | 22 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 36 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 343 | 0.100 |
Why?
|
| Melanoma | 1 | 2016 | 333 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 244 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 325 | 0.090 |
Why?
|
| New England | 2 | 2023 | 271 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 236 | 0.090 |
Why?
|
| Disease Progression | 2 | 2015 | 1219 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 222 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 408 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 730 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 102 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 524 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 739 | 0.080 |
Why?
|
| Adolescent | 2 | 2012 | 6305 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 8 | 0.080 |
Why?
|
| Pancreatic Fistula | 1 | 2010 | 19 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1113 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 223 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 118 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 20 | 0.070 |
Why?
|
| Logistic Models | 2 | 2013 | 1270 | 0.070 |
Why?
|
| Siblings | 1 | 2009 | 41 | 0.070 |
Why?
|
| Neoplasms | 1 | 2019 | 1367 | 0.070 |
Why?
|
| Pedigree | 1 | 2009 | 193 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2013 | 3307 | 0.070 |
Why?
|
| Cholangiography | 1 | 2008 | 43 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 2008 | 34 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 49 | 0.070 |
Why?
|
| Medicare | 1 | 2012 | 624 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 405 | 0.070 |
Why?
|
| Family | 1 | 2009 | 245 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 317 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 322 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1566 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 346 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2008 | 448 | 0.050 |
Why?
|
| Nipples | 1 | 2023 | 14 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2284 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 62 | 0.050 |
Why?
|
| Income | 1 | 2023 | 169 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 391 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 1656 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 48 | 0.040 |
Why?
|
| Students | 1 | 2022 | 225 | 0.040 |
Why?
|
| Mammography | 1 | 2021 | 290 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 37 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 94 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 962 | 0.030 |
Why?
|
| Mice | 1 | 2010 | 11105 | 0.030 |
Why?
|
| Chromogranins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 897 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 216 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 226 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 312 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 414 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 75 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 991 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Health Services | 1 | 2012 | 80 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 210 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 10 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1698 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 78 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 203 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 116 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1225 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 1392 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 21324 | 0.010 |
Why?
|